Saturday, June 17, 2017 4:18:30 PM
AHUS and Igan are no large scale phase 3's
Maiby 40 patients or so due to rare disease,the U.S.,Euro and Asia market value for IgA nephropathy is +$5B
At the ERA-EDTA meeting in Mardrid last week European & Asian institutions asked Omeros to participate in the phase 3 trial, so worldwide partnerships are already beeing forged. Next in pipeline is Immunotherapy and their addiction program, if they , in time , need to dilute for those it would be few 100k shares,They don't need that much. OMS527 would be phase 1. Those are cheap. And by then price could be 50 to 75
After phase 1 revenue will be sufficient to fund the rest of the trials
Yesterday was a shareholders meeting, not a CC , so imo no transcripts or replay
Over 90% of the outstanding shares were represented at the meeting
Quote from someone who was there
"Meeting was insanely positive. FDA basically begged them to go fast track for IGAN. Also, removed criteria that would make it take 2-3yrs for drug to market. Could be on market in a year. With 150k potential patients in US, cost of 70-100k per patient annually. Addiction drug potential unreal. Would be largest drug ever to come to market, 1-2 years aways from trials. 906 for arthritis scaling up for clinical trials. DR D believes recognition of OMER only beginning, wanted to be biggest pharma out of NW ever, thinks that now is conservative."
We also reached $1B market cap, the minimum m. Cap for some large institutions before they start buying,also 20% still shorted, if price continue to climb we will see a few squeezes in the proces
So to scale things up,2 five billion dollar products about to be launched between year end and half 2018 , start of Immunotherapy and 906 trials very soon and start trials for the MASSIVE OMS527 next year will make this a multi year runner
Addiction drug potential is beyond believe,Would be largest drug ever to come to market, pre trials were promising
$1000 company within 5 year
Sorry for the gramatical errors, i'm flemmish
Gltu
Recent OMER News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:56 PM
- Omeros Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:02:00 PM
- Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 • Business Wire • 08/05/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:07:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:53 PM
- Omeros Announces Webcast Details for Annual Meeting of Shareholders • Business Wire • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:00:24 PM
- Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 • Business Wire • 06/03/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:40 PM
- Omeros Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/15/2024 08:02:00 PM
- Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 • Business Wire • 05/10/2024 12:50:00 PM
- Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress • Business Wire • 05/09/2024 12:50:00 PM
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM